Update on heparin: what do we need to know?
- 2 November 2009
- journal article
- review article
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 29 (2) , 199-207
Abstract
Over the last 15 years, there has been a shift from unfractionated heparin to low-molecular-weight heparin or fondaparinux for many indications. Nonetheless, heparin continues to be used and it remains the drug of choice for selected indications and patients. This paper reviews when and how to use heparin and when low-molecular-weight heparin or fondaparinux may be a better choice. The paper also describes some of the new parenteral anticoagulants under development and provides perspective on how the introduction of rapid-acting oral thrombin or factor Xa inhibitors is likely to reduce or eliminate the need for bridging with parenteral anticoagulants.Keywords
This publication has 53 references indexed in Scilit:
- Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapyJournal of Thrombosis and Haemostasis, 2008
- Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients With Stable Coronary Artery DiseaseCirculation, 2008
- Fondaparinux for the treatment of patients with acute heparininduced thrombocytopeniaThrombosis and Haemostasis, 2008
- Extended Prophylaxis of Venous Thromboembolism with IdraparinuxNew England Journal of Medicine, 2007
- Idraparinux versus Standard Therapy for Venous Thromboembolic DiseaseNew England Journal of Medicine, 2007
- First-in-Human Experience of an Antidote-Controlled Anticoagulant Using RNA Aptamer TechnologyCirculation, 2006
- Minimising the risk of heparin-induced osteoporosis during pregnancyExpert Opinion on Drug Safety, 2005
- Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra®) on human osteoblasts in vitroBritish Journal of Surgery, 2005
- Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopeniaBlood, 2005
- Low-Molecular-Weight HeparinsNew England Journal of Medicine, 1997